Quinolones (ATC-group J01M): the state of the pharmaceutical market, analysis of consumption in Ukraine and in some European countries in 2013-2018

Abstract

The synthesis of the first antibiotic of the Quinolone group took place in 1958. Since then, Quinolones are widely used in clinical practice around the world due to their wide antibacterial spectrum of action.Aim. To study the pharmaceutical market of Ukraine of the Quinolone antibiotics group, as well as determine the volumes of their consumption in 2013-2018.Materials and methods. The analysis of the assortment of antibiotics of the Quinolone group was carried out according to the WHO Collaborating Center by methodologies for statistical analysis of drugs and according to the State Register of Medicines of Ukraine. The consumption was calculated using a standardized ATC/DDD methodology recommended by the WHO.Results. Eleven INNs of the Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones. In 2018, 159 trade names (TNs) of Quinolones were registered in Ukraine; 40.25 % of them are of domestic production (64 TNs). The consumption of Quinolones for the study period increased from 1.77 DID in 2016 to 1.83 DID in 2018. In general, the ABD consumption in the countries of the European Union and the European Economic Area (EU/EEA) decreased during the study period from с 1.77 DID in 2013 to 1.5 DID in 2018.Conclusions. Eleven INNs of Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones presented by 159 TNs in 2018. The consumption of Quinolones increased over the study period from 1.77 DID in 2016 to 1.83 DID in 2018. Within 2013-2016 the consumption of Quinolone antibiotics in Ukraine was lower than in the EU/EEA, but in 2017 the consumption in Ukraine increased to 0.15 DID, and in 2018 the difference increased to 0.33 DID.